WaterStone Capital
WaterStone Capital is a private investment fund manager that focuses on intellectual property as its primary asset. The firm offers equity investment financing to both Chinese and foreign enterprises that possess significant intellectual property content. In addition to funding, WaterStone Capital provides comprehensive post-investment management support, which includes cross-border capital operations, business collaborations, and resource integration. The team, comprised of professionals from both China and the United States, brings diverse expertise from leading institutions in their respective countries. Their collective experience spans international mergers and acquisitions, investment management, intellectual property rights, and independent entrepreneurship, enabling WaterStone Capital to effectively support the growth of its portfolio companies.
LumiThera
Series B in 2017
LumiThera, Inc. is a medical device company dedicated to developing innovative treatment solutions aimed at improving visual function and preventing vision loss associated with debilitating eye diseases. Founded in 2013 and based in Poulsbo, Washington, the company specializes in photobiomodulation therapy, utilizing non-invasive light-emitting diodes (LEDs) and laser treatments to address both acute and chronic ocular disorders. Its flagship product, The Valeda, is designed specifically for the treatment of dry age-related macular degeneration (AMD) and other ocular conditions. LumiThera's technology not only strives to halt or slow the progression of vision-threatening diseases but also aims to enhance visual acuity and contrast sensitivity in patients. Through its advancements in light therapy, LumiThera supports healthcare providers in offering improved treatment options for individuals affected by these common eye disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.